TransMedics Group, Inc. to Post Q2 2024 Earnings of $0.10 Per Share, William Blair Forecasts (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair lifted their Q2 2024 earnings estimates for TransMedics Group in a report released on Tuesday, April 30th. William Blair analyst R. Daniels now expects that the company will post earnings per share of $0.10 for the quarter, up from their previous forecast of ($0.11). The consensus estimate for TransMedics Group’s current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group’s Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.15) EPS, FY2024 earnings at $0.23 EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.28 EPS.

TMDX has been the subject of a number of other reports. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday. Oppenheimer raised their target price on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Morgan Stanley lifted their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.00.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $124.44 on Friday. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $124.52. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The stock’s 50-day simple moving average is $84.64 and its 200-day simple moving average is $76.26.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter last year, the firm earned ($0.08) EPS. The business’s quarterly revenue was up 132.9% on a year-over-year basis.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 736 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total transaction of $66,306.24. Following the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,047,155.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 736 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Insiders have sold 102,078 shares of company stock valued at $8,691,221 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. J.W. Cole Advisors Inc. purchased a new position in TransMedics Group during the third quarter valued at $929,000. Bank of New York Mellon Corp boosted its holdings in TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after buying an additional 363,012 shares during the last quarter. Shariaportfolio Inc. purchased a new stake in TransMedics Group during the 3rd quarter worth approximately $470,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of TransMedics Group by 12.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock valued at $378,000 after acquiring an additional 763 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in TransMedics Group by 12.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock valued at $818,000 after purchasing an additional 1,700 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.